Global study finds heart failure drug spironolactone fails to lower cardiovascular risk in dialysis patients

A large international study has found that spironolactone, a medication for high blood pressure and heart failure, does not reduce the risk of heart-related death or hospitalizations in people with kidney failure receiving dialysis, despite earlier smaller studies suggesting benefit.

Facebook Comments